Citadel Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Citadel Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-47,200	Closed	-$26K	–	8428
2016 Q3	$26K	Sell	47,200 -18,500	-28%	-$8.46K	﹤0.01%	6992
2016 Q2	$38K	Buy	65,700 +16,100	+32%	+$17.2K	﹤0.01%	6468
2016 Q1	$72K	Buy	49,600 +9,700	+24%	+$19.1K	﹤0.01%	6155
2015 Q4	$128K	Sell	39,900 -63,400	-61%	-$305K	﹤0.01%	6414
2015 Q3	$646K	Sell	103,300 -87,300	-46%	-$816K	﹤0.01%	4426
2015 Q2	$1.89M	Buy	190,600 +54,000	+40%	+$473K	﹤0.01%	3121
2015 Q1	$1.01M	Buy	136,600 +41,900	+44%	+$282K	﹤0.01%	3912
2014 Q4	$507K	Buy	94,700 +30,700	+48%	+$157K	﹤0.01%	4709
2014 Q3	$322K	Sell	64,000 -71,000	-53%	-$436K	﹤0.01%	5183
2014 Q2	$906K	Buy	135,000 +74,500	+123%	+$474K	﹤0.01%	3631
2014 Q1	$438K	Buy	+60,500	New	+$359K	﹤0.01%	4536

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Citadel Advisors's NWBO Position: Q4 2016 in Review

Citadel Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 17,627 shares — an estimated $10K sold.

Citadel Advisors first reported a position in NWBO in Q1 2014 and held it in 8 quarters. The position peaked at $192K in Q2 2014. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

Citadel Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
Citadel Advisors sold 17,627 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $10K.
Citadel Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 8 quarters.
Citadel Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $192K in Q2 2014.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.